Building Value-Based Care Models for Cell and Gene Therapy: Insights from Will Shrank
At the Asembia ASX26 Summit in Las Vegas, Aradigm Health CEO Will Shrank discussed the significant challenges facing the cell and gene therapy sector, particularly regarding high costs and fragmented healthcare infrastructure in the US. Shrank highlighted that providers, payers, and manufacturers struggle with unpredictability in volume, pricing, and patient retention, which hinders sustainable business models. He advocated for a systemic, ecosystem-wide approach involving collective action and broader risk pooling to manage financial volatility and improve affordability. Shrank also described Aradigm’s transparent 'entirely pass-through' business model, which charges only an administrative fee and returns any savings to purchasers as dividends, thereby aligning incentives and building trust. Furthermore, he noted that while payers are increasingly embracing value-based care models for these therapies, past efforts often lacked true financial alignment and clear outcome measurements. The interview emphasizes the need for transparency, collaboration, and innovative contracting strategies to ensure accessible and sustainable delivery of advanced cell and gene treatments.
Wire timeline
Building Value-Based Care Models for Cell and Gene Therapy: Insights from Will Shrank
At the Asembia ASX26 Summit in Las Vegas, Aradigm Health CEO Will Shrank discussed the significant challenges facing the cell and gene therapy sector, particularly regarding high costs and fragmented healthcare infrastructure in the US. Shrank highlighted that providers, payers, and manufacturers struggle with unpredictability in volume, pricing, and patient retention, which hinders sustainable business models. He advocated for a systemic, ecosystem-wide approach involving collective action and broader risk pooling to manage financial volatility and improve affordability. Shrank also described Aradigm’s transparent 'entirely pass-through' business model, which charges only an administrative fee and returns any savings to purchasers as dividends, thereby aligning incentives and building trust. Furthermore, he noted that while payers are increasingly embracing value-based care models for these therapies, past efforts often lacked true financial alignment and clear outcome measurements. The interview emphasizes the need for transparency, collaboration, and innovative contracting strategies to ensure accessible and sustainable delivery of advanced cell and gene treatments.
PharmExec articles